Market Research Logo

Seizures - Pipeline Review, H2 2015

Introduction
Global Markets Direct Report Coverage
Seizures Overview
Therapeutics Development
Pipeline Products for Seizures - Overview
Pipeline Products for Seizures - Comparative Analysis
Seizures - Therapeutics under Development by Companies
Seizures - Therapeutics under Investigation by Universities/Institutes
Seizures - Pipeline Products Glance
Late Stage Products
Clinical Stage Products
Early Stage Products
Seizures - Products under Development by Companies
Seizures - Products under Investigation by Universities/Institutes
Seizures - Companies Involved in Therapeutics Development
Advicenne Pharma
Alexza Pharmaceuticals, Inc.
Catalyst Pharmaceutical Partners, Inc.
Eisai Co., Ltd.
GW Pharmaceuticals Plc
H. Lundbeck A/S
INSYS Therapeutics, Inc.
Ligand Pharmaceuticals, Inc.
Marathon Pharmaceuticals, LLC
Marinus Pharmaceuticals, Inc.
Novartis AG
OPKO Health, Inc.
Retrophin Inc.
Sage Therapeutics
SciFluor Life Sciences, LLC
SK Biopharmaceuticals Co., Ltd.
UCB S.A.
Ultragenyx Pharmaceutical Inc.
Upsher-Smith Laboratories, Inc.
Xenon Pharmaceuticals Inc.
Zogenix, Inc.
Seizures - Therapeutics Assessment
Assessment by Monotherapy Products
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Drug Profiles
ADD-405008 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
ADV-6208 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
ADV-6770 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
alprazolam - Drug Profile
Product Description
Mechanism of Action
R&D Progress
AMPX-0079 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
AVL-5189 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
brivaracetam - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Cannabidiol - Drug Profile
Product Description
Mechanism of Action
R&D Progress
CCG-63802 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
CHEC-9 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
clobazam - Drug Profile
Product Description
Mechanism of Action
R&D Progress
cosyntropin - Drug Profile
Product Description
Mechanism of Action
R&D Progress
CPP-115 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
CUR-1916 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
diazepam - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Epidiolex - Drug Profile
Product Description
Mechanism of Action
R&D Progress
everolimus - Drug Profile
Product Description
Mechanism of Action
R&D Progress
fenfluramine hydrochloride - Drug Profile
Product Description
Mechanism of Action
R&D Progress
fosphenytoin sodium - Drug Profile
Product Description
Mechanism of Action
R&D Progress
ganaxolone - Drug Profile
Product Description
Mechanism of Action
R&D Progress
lacosamide - Drug Profile
Product Description
Mechanism of Action
R&D Progress
levetiracetam - Drug Profile
Product Description
Mechanism of Action
R&D Progress
MB-003 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
midazolam hydrochloride - Drug Profile
Product Description
Mechanism of Action
R&D Progress
MP-102 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
NRP-2945 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Oligonucleotide for Dravet Syndrome - Drug Profile
Product Description
Mechanism of Action
R&D Progress
perampanel - Drug Profile
Product Description
Mechanism of Action
R&D Progress
SAGE-217 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
SAGE-689 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
selurampanel - Drug Profile
Product Description
Mechanism of Action
R&D Progress
sepranolone - Drug Profile
Product Description
Mechanism of Action
R&D Progress
SF-0034 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Small Molecule to Inhibit GABA Transaminase for Migraine and Status Epilepticus - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Small Molecules to Activate TrkB Receptor for Central Nervous System, Metabolic Disorders and ENT Disorders - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Small Molecules to Inhibit Nav1.6 for Dravet Syndrome - Drug Profile
Product Description
Mechanism of Action
R&D Progress
TG-4155 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
UX-007 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
YKP-3089 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Seizures - Recent Pipeline Updates
Seizures - Dormant Projects
Seizures - Discontinued Products
Seizures - Product Development Milestones
Featured News & Press Releases
Sep 14, 2015: Eisai Announces FDA Acceptance of NDA for the Review of FYCOMPA (perampanel) Oral Suspension for Adjunctive Therapy in the Treatment of Partial-Onset Seizures and Primary Generalized Tonic-Clonic Seizures in Patients with Epilepsy Age 12 and Older
Sep 09, 2015: Marinus Pharmaceuticals Announces Positive End-of-Phase 2 Meeting With FDA for Ganaxolone in Focal Onset Seizures
Aug 24, 2015: FYCOMPA (perampanel) CIII Demonstrates a Significant Reduction in Primary Generalized Tonic-Clonic Seizure Frequency in Phase 3 Trial of Patients with Epilepsy Age 12 and Older
Aug 17, 2015: SAGE Announces First Patient Treated in Phase 3 STATUS Trial of SAGE-547 in Super-Refractory Status Epilepticus
Aug 06, 2015: SAGE Receives Special Protocol Assessment for Phase 3 STATUS Trial of SAGE-547 in Super-Refractory Status Epilepticus
Aug 04, 2015: Insys Therapeutics Receives FDA Orphan Drug Designation for Its Pharmaceutical Cannabidiol for the Treatment of Infantile Spasms
Jul 27, 2015: Eisai Submits New Drug Application In Japan For In-House-Discovered Antiepileptic Drug Perampanel As Adjunctive Therapy For Partial-Onset And Generalized Tonic-Clonic Seizures
Jul 08, 2015: First-in-Class Epilepsy Treatment Fycompa (Perampanel) Launches in the United Kingdom for Primary Generalised Tonic-Clonic Seizures
Jun 25, 2015: European Commission Approves Indication Expansion Of Eisai’s Antiepileptic Agent Fycompa For Adjunctive Treatment Of Primary Generalized Tonic-Clonic Seizures
Jun 22, 2015: U.S. FDA Approves Eisai’s Antiepileptic Agent Fycompa As Adjunctive Treatment For Primary Generalized Tonic-Clonic Seizures
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer
List of Tables
Number of Products under Development for Seizures, H2 2015
Number of Products under Development for Seizures - Comparative Analysis, H2 2015
Number of Products under Development by Companies, H2 2015
Number of Products under Investigation by Universities/Institutes, H2 2015
Comparative Analysis by Late Stage Development, H2 2015
Comparative Analysis by Clinical Stage Development, H2 2015
Comparative Analysis by Early Stage Development, H2 2015
Products under Development by Companies, H2 2015
Products under Development by Companies, H2 2015 (Contd..1)
Products under Development by Companies, H2 2015 (Contd..2)
Products under Development by Companies, H2 2015 (Contd..3)
Products under Investigation by Universities/Institutes, H2 2015
Seizures - Pipeline by Advicenne Pharma, H2 2015
Seizures - Pipeline by Alexza Pharmaceuticals, Inc., H2 2015
Seizures - Pipeline by Catalyst Pharmaceutical Partners, Inc., H2 2015
Seizures - Pipeline by Eisai Co., Ltd., H2 2015
Seizures - Pipeline by GW Pharmaceuticals Plc, H2 2015
Seizures - Pipeline by H. Lundbeck A/S, H2 2015
Seizures - Pipeline by INSYS Therapeutics, Inc., H2 2015
Seizures - Pipeline by Ligand Pharmaceuticals, Inc., H2 2015
Seizures - Pipeline by Marathon Pharmaceuticals, LLC, H2 2015
Seizures - Pipeline by Marinus Pharmaceuticals, Inc., H2 2015
Seizures - Pipeline by Novartis AG, H2 2015
Seizures - Pipeline by OPKO Health, Inc., H2 2015
Seizures - Pipeline by Retrophin Inc., H2 2015
Seizures - Pipeline by Sage Therapeutics, H2 2015
Seizures - Pipeline by SciFluor Life Sciences, LLC, H2 2015
Seizures - Pipeline by SK Biopharmaceuticals Co., Ltd., H2 2015
Seizures - Pipeline by UCB S.A., H2 2015
Seizures - Pipeline by Ultragenyx Pharmaceutical Inc., H2 2015
Seizures - Pipeline by Upsher-Smith Laboratories, Inc., H2 2015
Seizures - Pipeline by Xenon Pharmaceuticals Inc., H2 2015
Seizures - Pipeline by Zogenix, Inc., H2 2015
Assessment by Monotherapy Products, H2 2015
Number of Products by Stage and Target, H2 2015
Number of Products by Stage and Mechanism of Action, H2 2015
Number of Products by Stage and Route of Administration, H2 2015
Number of Products by Stage and Molecule Type, H2 2015
Seizures Therapeutics - Recent Pipeline Updates, H2 2015
Seizures - Dormant Projects, H2 2015
Seizures - Dormant Projects (Contd..1), H2 2015
Seizures - Discontinued Products, H2 2015
List of Figures
Number of Products under Development for Seizures, H2 2015
Number of Products under Development for Seizures - Comparative Analysis, H2 2015
Number of Products under Development by Companies, H2 2015
Comparative Analysis by Late Stage Development, H2 2015
Comparative Analysis by Clinical Stage Development, H2 2015
Comparative Analysis by Early Stage Products, H2 2015
Assessment by Monotherapy Products, H2 2015
Number of Products by Top 10 Targets, H2 2015
Number of Products by Stage and Top 10 Targets, H2 2015
Number of Products by Top 10 Mechanism of Actions, H2 2015
Number of Products by Stage and Top 10 Mechanism of Actions, H2 2015
Number of Products by Top 10 Routes of Administration, H2 2015
Number of Products by Stage and Top 10 Routes of Administration, H2 2015
Number of Products by Top 10 Molecule Types, H2 2015
Number of Products by Stage and Top 10 Molecule Types, H2 2015

Seizures - Pipeline Review, H2 2015

Summary

Global Markets Direct’s, ‘Seizures - Pipeline Review, H2 2015’, provides an overview of the Seizures’s therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Seizures, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Seizures and special features on late-stage and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

  • The report provides a snapshot of the global therapeutic landscape of Seizures
  • The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved in the therapeutics development for Seizures and enlists all their major and minor projects
  • The report summarizes all the dormant and discontinued pipeline projects
  • A review of the Seizures products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
  • Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • A detailed assessment of monotherapy and combination therapy pipeline projects
  • Coverage of the Seizures pipeline on the basis of target, MoA, route of administration and molecule type
  • Latest news and deals relating related to pipeline products
Reasons to buy
  • Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Identify and understand important and diverse types of therapeutics under development for Seizures
  • Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
  • Devise corrective measures for pipeline projects by understanding Seizures pipeline depth and focus of Indication therapeutics
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
  • Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline


Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook

Share this report

;